<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37047126</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Epstein-Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24076156</ELocationID><Abstract><AbstractText>Although Epstein-Barr virus (EBV) reactivation has long been associated with the pathogenesis of systemic lupus erythematosus (SLE), many aspects of this relationship remain unclear. Our objective was to investigate the association between EBV reactivation and the achievement of SLE remission and lupus low disease activity state (LLDAS) over a six-month period. Clinical, laboratory, and virological tests (anti-EBV antibodies and EBV DNA) were performed among 51 patients with the active form of SLE on two occasions six months apart. SLE remission and LLDAS achievement were assessed at the end of the follow-up period. Active EBV infection was detected in 45% of active SLE patients at baseline, and 77% transitioned to latent EBV infection at six months (<i>p</i> &lt; 0.001). Multivariate regression revealed a higher titer of anti-EA(D) IgM-Abs and the presence of anti-EA(D) IgM-Abs as independent predictors of remission and LLDAS in SLE patients with mucocutaneous manifestations (<i>p</i> = 0.042) and rash only (<i>p</i> = 0.023), respectively. Since a higher C3 level was an independent predictor of transition to latent EBV infection (<i>p</i> = 0.027), the estimated cut-off value that could identify active SLE patients who will transition to latent EBV infection after six months was &#x2265;0.780 g/L with a sensitivity of 70.6% and a specificity of 75.0% (AUC = 0.756, <i>p</i> = 0.003). EBV reactivation is common in patients with active SLE, and most of them transition to latent EBV infection after six months. Achieving remission and LLDAS in SLE patients with mucocutaneous manifestations can be predicted by a higher titer, whereas in SLE patients who have only a rash, the presence of anti-EA (D) IgM-Abs was a predictor of remission and LLDAS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miskovic</LastName><ForeName>Rada</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0982-2572</Identifier><AffiliationInfo><Affiliation>Clinic of Allergy and Immunology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal medicine department, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirkovic</LastName><ForeName>Andja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miljanovic</LastName><ForeName>Danijela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9446-8701</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeremic</LastName><ForeName>Ivica</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Internal medicine department, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Rheumatology, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grk</LastName><ForeName>Milka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7534-9608</Identifier><AffiliationInfo><Affiliation>Institute of Human Genetics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basaric</LastName><ForeName>Milica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Rheumatology, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarevic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6795-1378</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojanovic</LastName><ForeName>Maja</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4589-7344</Identifier><AffiliationInfo><Affiliation>Clinic of Allergy and Immunology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal medicine department, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plavsic</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic of Allergy and Immunology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal medicine department, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raskovic</LastName><ForeName>Sanvila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic of Allergy and Immunology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal medicine department, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banko</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6829-096X</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>6060866, ROLERS</GrantID><Agency>Science Fund of the Republic of Serbia, PROMIS</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EBV reactivation</Keyword><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus (EBV)</Keyword><Keyword MajorTopicYN="N">SLE remission</Keyword><Keyword MajorTopicYN="N">anti-EA (D) IgM</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">lupus low disease activity state</Keyword><Keyword MajorTopicYN="N">predictor</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37047126</ArticleId><ArticleId IdType="pmc">PMC10093904</ArticleId><ArticleId IdType="doi">10.3390/ijms24076156</ArticleId><ArticleId IdType="pii">ijms24076156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C., Lo M.S., Reis P.C., Sullivan K.E. New Insights into the Immunopathogenesis of Systemic Lupus Erythematosus. Nat. Rev. Rheumatol. 2016;12:716&#x2013;730. doi: 10.1038/nrrheum.2016.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L., Leonard D. Interferon Pathway in SLE: One Key to Unlocking the Mystery of the Disease. Lupus Sci. Med. 2019;6:e000270. doi: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Q., Liu Z., Liao S., Ye L., Lu X., Chen X., Li Z., Li X., Xu Y.Z., Liu H. Current Mechanistic Insights into the Role of Infection in Systemic Lupus Erythematosus. Biomed. Pharmacother. 2019;117:109122. doi: 10.1016/j.biopha.2019.109122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109122</ArticleId><ArticleId IdType="pubmed">31226637</ArticleId></ArticleIdList></Reference><Reference><Citation>Babcock G.J., Hochberg D., Thorley-Lawson D.A. The Expression Pattern of Epstein-Barr Virus Latent Genes in Vivo Is Dependent upon the Differentiation Stage of the Infected B Cell. Immunity. 2000;13:497&#x2013;506. doi: 10.1016/S1074-7613(00)00049-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)00049-2</ArticleId><ArticleId IdType="pubmed">11070168</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Duus K., Houen G. Epstein-Barr Virus in Systemic Autoimmune Diseases. Clin. Dev. Immunol. 2013;2013:535738. doi: 10.1155/2013/535738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/535738</ArticleId><ArticleId IdType="pmc">PMC3766599</ArticleId><ArticleId IdType="pubmed">24062777</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A., Izarzugaza J.M.G., Houen G. How Compelling Are the Data for Epstein-Barr Virus Being a Trigger for Systemic Lupus and Other Autoimmune Diseases? Curr. Opin. Rheumatol. 2016;28:398&#x2013;404. doi: 10.1097/BOR.0000000000000289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000289</ArticleId><ArticleId IdType="pubmed">26986247</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P., Tran H., Ebegbe R., Gottlieb P., Wei H., Lewis R.H., Mumbey-Wafula A., Kaplan A., Kholdarova E., Spatz L. Antibodies Elicited in Response to EBNA-1 May Cross-React with DsDNA. PLoS ONE. 2011;6:e14488. doi: 10.1371/journal.pone.0014488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0014488</ArticleId><ArticleId IdType="pmc">PMC3014975</ArticleId><ArticleId IdType="pubmed">21245919</ArticleId></ArticleIdList></Reference><Reference><Citation>James J.A., Harley J.B., Scofield R.H. Epstein-Barr Virus and Systemic Lupus Erythematosus. Curr. Opin. Rheumatol. 2006;18:462&#x2013;467. doi: 10.1097/01.bor.0000240355.37927.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.bor.0000240355.37927.94</ArticleId><ArticleId IdType="pubmed">16896283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jog N.R., James J.A. Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. Front. Immunol. 2021;11:623944. doi: 10.3389/fimmu.2020.623944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.623944</ArticleId><ArticleId IdType="pmc">PMC7886683</ArticleId><ArticleId IdType="pubmed">33613559</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglia M., Merlotti G., De Andrea M., Borgogna C., Cantaluppi V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses. 2021;13I:277. doi: 10.3390/v13020277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020277</ArticleId><ArticleId IdType="pmc">PMC7916951</ArticleId><ArticleId IdType="pubmed">33670195</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., Jacobsen S., Westergaard M., Mortensen S., Larsen J.L., Houen G., Duus K. Reduced Response to Epstein-Barr Virus Antigens by T-Cells in Systemic Lupus Erythematosus Patients. Lupus Sci. Med. 2014;1:e000015. doi: 10.1136/lupus-2014-000015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000015</ArticleId><ArticleId IdType="pmc">PMC4225738</ArticleId><ArticleId IdType="pubmed">25396062</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan T.E., Roman R.M., Rudenga B.J., Holers V.M., Craft J.E. Epstein-Barr Virus Promotes Interferon-Alpha Production by Plasmacytoid Dendritic Cells. Arthritis Rheum. 2010;62:1693&#x2013;1701. doi: 10.1002/art.27408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27408</ArticleId><ArticleId IdType="pmc">PMC2885535</ArticleId><ArticleId IdType="pubmed">20178121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chougule D., Nadkar M., Rajadhyaksha A., Pandit-Shende P., Surve P., Dawkar N., Khadilkar P., Patwardhan M., Kaveri S., Ghosh K., et al. Association of Clinical and Serological Parameters of Systemic Lupus Erythematosus Patients with Epstein-Barr Virus Antibody Profile. J. Med. Virol. 2018;90:559&#x2013;563. doi: 10.1002/jmv.24904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24904</ArticleId><ArticleId IdType="pubmed">28734074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;a S.A.D.S., Viana J.B.G.d.O., G&#xf3;es H.C.A., Fonseca R.R.D.S., Laurentino R.V., Costa I.B., Oliveira-Filho A.B., Machado L.F.A. Epidemiology of the Epstein-Barr Virus in Autoimmune Inflammatory Rheumatic Diseases in Northern Brazil. Viruses. 2022;14:694. doi: 10.3390/v14040694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14040694</ArticleId><ArticleId IdType="pmc">PMC9028150</ArticleId><ArticleId IdType="pubmed">35458425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood R.A., Guthridge L., Thurmond E., Guthridge C.J., Kheir J.M., Bourn R.L., Wagner C.A., Chen H., DeJager W., Macwana S.R., et al. Serologic Markers of Epstein-Barr Virus Reactivation Are Associated with Increased Disease Activity, Inflammation, and Interferon Pathway Activation in Patients with Systemic Lupus Erythematosus. J. Transl. Autoimmun. 2021;4:100117. doi: 10.1016/j.jtauto.2021.100117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100117</ArticleId><ArticleId IdType="pmc">PMC8716608</ArticleId><ArticleId IdType="pubmed">35005588</ArticleId></ArticleIdList></Reference><Reference><Citation>Vista E.S., Weisman M.H., Ishimori M.L., Chen H., Bourn R.L., Bruner B.F., Hamijoyo L., Tanangunan R.D., Gal N.J., Robertson J.M., et al. Strong Viral Associations with SLE among Filipinos. Lupus Sci. Med. 2017;4:e000214. doi: 10.1136/lupus-2017-000214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000214</ArticleId><ArticleId IdType="pmc">PMC5704743</ArticleId><ArticleId IdType="pubmed">29214036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen N., Draborg A., Nielsen C., Jacobsen S., Houen G. Antibodies to Early EBV, CMV, and HHV6 Antigens in Systemic Lupus Erythematosus Patients. Scand. J. Rheumatol. 2015;44:143&#x2013;149. doi: 10.3109/03009742.2014.973061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2014.973061</ArticleId><ArticleId IdType="pmc">PMC4389709</ArticleId><ArticleId IdType="pubmed">25562120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon P., Avenell A., Aucott L., Vickers M.A. Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein-Barr Virus and Systemic Lupus Erythematosus. Arthritis Res. Ther. 2014;16:R3. doi: 10.1186/ar4429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4429</ArticleId><ArticleId IdType="pmc">PMC3978841</ArticleId><ArticleId IdType="pubmed">24387619</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.X., Zeng S., Wu H.X., Zhou Y. The Risk of Systemic Lupus Erythematosus Associated with Epstein&#x2013;Barr Virus Infection: A Systematic Review and Meta-Analysis. Clin. Exp. Med. 2019;19:23&#x2013;36. doi: 10.1007/s10238-018-0535-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-018-0535-0</ArticleId><ArticleId IdType="pmc">PMC6394567</ArticleId><ArticleId IdType="pubmed">30361847</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L., Zhang Y., Wang Q., Xin M., Yang K., Lei K., Sun M. Epstein&#x2013;Barr Virus Infection and Type I Interferon Signature in Patients with Systemic Lupus Erythematosus. Lupus. 2018;27:947&#x2013;954. doi: 10.1177/0961203317753069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317753069</ArticleId><ArticleId IdType="pubmed">29338588</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins M.L., Todd I., Powell R.J. Reactivation of Epstein-Barr Virus in Patients with Systemic Lupus Erythematosus. Rheumatol. Int. 2005;25:183&#x2013;187. doi: 10.1007/s00296-003-0420-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-003-0420-2</ArticleId><ArticleId IdType="pubmed">14666378</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P., Minz R.W., Saikia B., Sharma A., Anand S., Singh H., Singh S. Association of Human Leucocyte Antigen Class II, with Viral Load and Immune Response to Epstein-Barr Virus in Adult and Pediatric Systemic Lupus Erythematosus Patients. Lupus. 2022;31:1054&#x2013;1066. doi: 10.1177/09612033221100156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221100156</ArticleId><ArticleId IdType="pubmed">35607991</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternb&#xe6;k L., Draborg A.H., &#xd8;sterlund M.T., Iversen L.V., Troelsen L., Theander E., Nielsen C.T., Jacobsen S., Houen G. Increased Antibody Levels to Stage-Specific Epstein&#x2013;Barr Virus Antigens in Systemic Autoimmune Diseases Reveal a Common Pathology. Scand. J. Clin. Lab. Investig. 2019;79:7&#x2013;16. doi: 10.1080/00365513.2018.1550807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2018.1550807</ArticleId><ArticleId IdType="pubmed">30727744</ArticleId></ArticleIdList></Reference><Reference><Citation>Truszewska A., Wirkowska A., Gala K., Truszewski P., Krzemie&#x144;-Ojak &#x141;., Mucha K., P&#x105;czek L., Foroncewicz B. EBV Load Is Associated with CfDNA Fragmentation and Renal Damage in SLE Patients. Lupus. 2021;30:1214&#x2013;1225. doi: 10.1177/09612033211010339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211010339</ArticleId><ArticleId IdType="pubmed">33866897</ArticleId></ArticleIdList></Reference><Reference><Citation>Aygun D., Kuskucu M.A., Sahin S., Adrovic A., Barut K., Yildiz M., Sharifova S., Midilli K., Cokugras H., Camc&#x131;oglu Y., et al. Epstein-Barr Virus, Cytomegalovirus and BK Polyomavirus Burden in Juvenile Systemic Lupus Erythematosus: Correlation with Clinical and Laboratory Indices of Disease Activity. Lupus. 2020;29:1263&#x2013;1269. doi: 10.1177/0961203320940029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320940029</ArticleId><ArticleId IdType="pubmed">32646294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen N.S., Nielsen C.T., Houen G., Jacobsen S. Humoral Markers of Active Epstein-Barr Virus Infection Associate with Anti-Extractable Nuclear Antigen Autoantibodies and Plasma Galectin-3 Binding Protein in Systemic Lupus Erythematosus. Lupus. 2016;25:1567&#x2013;1576. doi: 10.1177/0961203316644334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316644334</ArticleId><ArticleId IdType="pubmed">27084029</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon U.Y., Park S.J., Oh S.T., Kim W.U., Park S.H., Lee S.H., Cho C.S., Kim H.Y., Lee W.K., Lee S.K. Patients with Systemic Lupus Erythematosus Have Abnormally Elevated Epstein-Barr Virus Load in Blood. Arthritis Res. Ther. 2004;6:R295&#x2013;R302. doi: 10.1186/ar1181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1181</ArticleId><ArticleId IdType="pmc">PMC464871</ArticleId><ArticleId IdType="pubmed">15225364</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg A.H., J&#xf8;rgensen J.M., M&#xfc;ller H., Nielsen C.T., Jacobsen S., Iversen L.V., Theander E., Nielsen L.P., Houen G., Duus K. Epstein-Barr Virus Early Antigen Diffuse (EBV-EA/D)-Directed Immunoglobulin A Antibodies in Systemic Lupus Erythematosus Patients. Scand. J. Rheumatol. 2012;41:280&#x2013;289. doi: 10.3109/03009742.2012.665944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.665944</ArticleId><ArticleId IdType="pubmed">22646970</ArticleId></ArticleIdList></Reference><Reference><Citation>Esen B.A., YIlmaz G., Uzun S., &#xd6;zdamar M., Aks&#xf6;zek A., KamalI S., T&#xfc;rko&#x1e7;lu S., G&#xfc;l A., &#xd6;cal L., Aral O., et al. Serologic Response to Epstein-Barr Virus Antigens in Patients with Systemic Lupus Erythematosus: A Controlled Study. Rheumatol. Int. 2012;32:79&#x2013;83. doi: 10.1007/s00296-010-1573-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1573-4</ArticleId><ArticleId IdType="pubmed">20661740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman-Goddard G., Berkun Y., Barzilai O., Boaz M., Blank M., Ram M., Sherer Y., Anaya J.M., Shoenfeld Y. Exposure to Epstein-Barr Virus Infection Is Associated with Mild Systemic Lupus Erythematosus Disease. Ann. N. Y. Acad. Sci. 2009;1173:658&#x2013;663. doi: 10.1111/j.1749-6632.2009.04754.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04754.x</ArticleId><ArticleId IdType="pubmed">19758212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J., Wang X., Geng G., Xue X., Lin X., Zhu X., Sun L. The Possible Effect of B-Cell Epitopes of Epstein-Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus. Front. Immunol. 2018;9:187. doi: 10.3389/fimmu.2018.00187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00187</ArticleId><ArticleId IdType="pmc">PMC5819577</ArticleId><ArticleId IdType="pubmed">29497417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mold C., Bradt B.M., Nemerow G.R., Cooper N.R. Epstein-Barr Virus Regulates Activation and Processing of the Third Component of Complement. J. Exp. Med. 1988;168:949. doi: 10.1084/jem.168.3.949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.168.3.949</ArticleId><ArticleId IdType="pmc">PMC2189017</ArticleId><ArticleId IdType="pubmed">2844953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jondal M., Klein G., Oldstone M.B.A., Bokish V., Yefenof E. Surface Markers on Human B and T Lymphocytes. VIII. Association between Complement and Epstein-Barr Virus Receptors on Human Lymphoid Cells. Scand. J. Immunol. 1976;5:401&#x2013;410. doi: 10.1111/j.1365-3083.1976.tb00294.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1976.tb00294.x</ArticleId><ArticleId IdType="pubmed">59946</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemerow G.R., Mold C., Schwend V.K., Tollefson V., Cooper N.R. Identification of Gp350 as the Viral Glycoprotein Mediating Attachment of Epstein-Barr Virus (EBV) to the EBV/C3d Receptor of B Cells: Sequence Homology of Gp350 and C3 Complement Fragment C3d. J. Virol. 1987;61:1416&#x2013;1420. doi: 10.1128/jvi.61.5.1416-1420.1987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.61.5.1416-1420.1987</ArticleId><ArticleId IdType="pmc">PMC254117</ArticleId><ArticleId IdType="pubmed">3033269</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell I., Klein G., Lint T.F., Lachmann P.J. Activation of the Alternative Complement Pathway by Human B Cell Lymphoma Lines Is Associated with Epstein-Barr Virus Transformation of the Cells. Eur. J. Immunol. 1978;8:453&#x2013;458. doi: 10.1002/eji.1830080702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830080702</ArticleId><ArticleId IdType="pubmed">211040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mold C., Bradt B.M., Nemerow G.R., Cooper N.R. Activation of the Alternative Complement Pathway by EBV and the Viral Envelope Glycoprotein, Gp350. J. Immunol. 1988;140:3867&#x2013;3874. doi: 10.4049/jimmunol.140.11.3867.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.140.11.3867</ArticleId><ArticleId IdType="pubmed">2836501</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan J., Ji Z., Wang B., Zeng X., Chen R., He Y., Rao P., Wu P., Shi G. Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sj&#xf6;gren&#x2019;s Syndrome. Front. Immunol. 2020;11:2826. doi: 10.3389/fimmu.2020.590444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.590444</ArticleId><ArticleId IdType="pmc">PMC7662096</ArticleId><ArticleId IdType="pubmed">33193425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Ann. Rheum. Dis. 2019;78:1151&#x2013;1159. doi: 10.1136/annrheumdis-2018-214819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Iba&#xf1;ez D., Urowltz M.B. Systemic Lupus Erythematosus Disease Activity Index 2000. J. Rheumatol. 2002;29:288&#x2013;291. doi: 10.1016/b978-0-323-04434-9.50060-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-323-04434-9.50060-9</ArticleId><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M., Chessa E., Morand E.F., Ugarte-Gil M.F., Tektonidou M., van Vollenhoven R., Petri M., Arnaud L., Appenzeller S., Aranow C., et al. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: The PISCOS Study. Lancet Rheumatol. 2022;4:e441&#x2013;e449. doi: 10.1016/S2665-9913(22)00107-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00107-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K., Gladman D.D., Urowitz M.B. How Can We Define Low Disease Activity in Systemic Lupus Erythematosus? Semin. Arthritis Rheum. 2019;48:1035&#x2013;1040. doi: 10.1016/j.semarthrit.2018.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.10.013</ArticleId><ArticleId IdType="pubmed">30415943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M., Iaccarino L., Gatto M., Saccon F., Larosa M., Ghirardello A., Punzi L., Doria A. Lupus Low Disease Activity State Is Associated with a Decrease in Damage Progression in Caucasian Patients with SLE, but Overlaps with Remission. Ann. Rheum. Dis. 2018;77:104&#x2013;110. doi: 10.1136/annrheumdis-2017-211613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211613</ArticleId><ArticleId IdType="pubmed">28970217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang-A-Sjoe M.W.P., Bultink I.E.M., Heslinga M., Voskuyl A.E. Both Prolonged Remission and Lupus Low Disease Activity State Are Associated with Reduced Damage Accrual in Systemic Lupus Erythematosus. Rheumatology. 2017;56:121&#x2013;128. doi: 10.1093/rheumatology/kew377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew377</ArticleId><ArticleId IdType="pubmed">27803306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzetti M.A., Altcheh J., Moroni S., Moscatelli G., Chabay P.A., Preciado M.V. EBNA1 Sequences in Argentinean Pediatric Acute and Latent Epstein-Barr Virus Infection Reflect Circulation of Novel South American Variants. J. Med. Virol. 2010;82:1730&#x2013;1738. doi: 10.1002/jmv.21871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21871</ArticleId><ArticleId IdType="pubmed">20827771</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko A., Lazarevic I., Stevanovic G., Cirkovic A., Karalic D., Cupic M., Banko B., Milovanovic J., Jovanovic T. Analysis of the Variability of Epstein-Barr Virus Genes in Infectious Mononucleosis: Investigation of the Potential Correlation with Biochemical Parameters of Hepatic Involvement. J. Med. Biochem. 2016;35:337. doi: 10.1515/jomb-2015-0021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jomb-2015-0021</ArticleId><ArticleId IdType="pmc">PMC5346813</ArticleId><ArticleId IdType="pubmed">28356886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>